Longenesis joins forces with Northern European oncologists, academia and female oncology patient association to launch digital pre-screening program for early diagnostics and proactive involvement in breast and cervical cancer-related studies

14th of January 2020, San Francisco, USA
Longenesis, a company based out of Asian and Northern Europe, disrupting an industry for compliant
access to medical data for clinical studies, formed a partnership alliance together with DF LAB
Healthcare Technology Project Laboratory (University of Latvia), VITA female oncology patient
association to launch a digital breast and cervical cancer pre-screening program for early diagnostics and proactive involvement in cancer-related studies in Northern European region.

Partners propose a new model for breast cancer-related risk calculation. It is based on a web interface and involves multiple data types, such as phenotypic metrics (survey results), visual red flags (early breast cancer symptoms), self-examination tool and genotypic data (genotypic result upload form). The model is implemented in a web-based tool where users have the ability to proactively enter the data into the platform and receive a customized report + “how-to” instructions for performing a standard screening in the Baltic region and receiving subsidized ancestor mutations genotypic testing. The model also allows users to provide their digital consent for input data processing and consent for potential participation in follow-on virtual studies, such as additional questionnaires, etc.

As a result, a tool developed by Longenesis will serve to:
- Educate and raise awareness about breast and cervical cancer-related risks;
- Involve patients/users into virtual study onboarding and access to new diagnostics,
assessment and treatment tools;
- correlate multiple data types (genotypic, phenotypic, visual) for risk assessment.

The project currently involves resident doctors, researchers for potential epidemiological studies and aims to reach 15 000 female participants in Q1 2020. The results will be published and showcased to the National Healthcare Service as a novel approach for population-wide cancer risk assessment and
preventive healthcare. The web-based platform will be publically available starting early February 2020.

About Longenesis:

Longenesis is a partnership between Insilico Medicine, a leading artificial intelligence company that uses deep learning for drug discovery, and the Bitfury Group, the leading full-service blockchain technology company. Longenesis is the exclusive healthcare application provider for open-source framework ExonumTM. The main goal of the company is to disrupt an industry for compliant access to medical data for clinical studies with a set of technological tools developed for pharma, clinics, researchers, data analytics companies, and patients’ proactive involvement in clinical and research studies, generating prospective biomedical data for insights generation.